ESR2 and breast carcinoma: In this study, simvastatin was validated to have antagonistic effects on ERβ with IC50 value at 3.12 μM and showed good antiproliferative activity on human MDA-MB-231 breast cancer cell line with IC50 value of 1.49 μM (Figures 5 and 6).